StockData

Indaptus Therapeutics, Inc. (INDP) shareholders

INDPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 5/30
$3.17+0.02 (+0.63%)

Close on Nov 13, 2026Market cap $422.38MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
0.3%
0M of 133M shares
Institutional holders
9
6 new, 2 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Yao Yun41,991,00027.34%13D (active) amendmentOct 16, 2026
Chenhao Xu
Joint filing with Sino Lion Ventures Ltd (29.19%)
38,895,00029.19%13D (active) amendmentJun 24, 2026
Sino Lion Ventures Ltd
Joint filing with Chenhao Xu (25.32%)
38,895,00025.32%13D (active) amendmentOct 16, 2026
Dai Junyi11,250,0007.33%13D (active) amendmentOct 16, 2026
Yang Ting9,948,1736.48%13D (active) amendmentOct 16, 2026
Lazar David E.2,064,00047.93%13D (active) amendmentMar 23, 2026
YA II PN, Ltd.
Joint filing with YA Global Investments II (U.S.), LP (9.99%), Yorkville Advisors Global, LP (9.99%) and 5 more
1,410,9169.99%13G (passive)Feb 13, 2025
Jeffery A. Meckler273,10312.70%13D (active) amendmentDec 22, 2025
Newman Michael James115,5525.40%13D (active) amendmentDec 22, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of INDPValueChange% of portfolio
Hrt Financial LP206,0770.15%$618.00KNew0.00%
Geode Capital Management, LLC56,4700.04%$169.41K+29,4630.00%
Jane Street Group, LLC53,8110.04%$161.43KNew0.00%
Vanguard Capital Management LLC33,6520.03%$100.96KNew0.00%
Vanguard Fiduciary Trust Co13,9670.01%$41.90KNew0.00%
Millennium Management LLC11,5860.01%$34.76KNew0.00%
Morgan Stanley8,9360.01%$26.81K+6,2390.00%
UBS Group AG4780.00%$1.43KNew0.00%
SBI Securities Co., Ltd.170.00%$51–0.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202690M0.3%6 / 20 / 20M0M
Q1 202660M0.1%4 / 01 / 20M0M
Q4 202540M0.0%0 / 21 / 10M0M
Q3 202550M0.0%2 / 21 / 20M0M
Q2 202550M0.0%1 / 12 / 150M0M
Q1 2025190M0.0%1 / 53 / 20M0M
Q4 2024200M0.0%3 / 43 / 10M0M
Q3 2024180M0.0%1 / 34 / 40M0M
Q2 2024210M0.0%5 / 34 / 10M0M
Q1 2024170M0.0%1 / 25 / 30M0M
Q4 2023190M0.0%3 / 51 / 00M0M
Q3 2023160M0.0%2 / 44 / 10M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

4 funds held INDP in Q2 2026, 29% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of INDPValue% of fundAs of
Fidelity Extended Market Index Fund17,6400.01%$31.05K0.00%May 31, 2026
Vanguard Extended Market Index Fund9,1420.01%$27.43K0.00%Jun 30, 2026
Fidelity Series Total Market Index Fund3,9290.00%$6.92K0.00%May 31, 2026
Fidelity Total Market Index Fund4620.00%$8130.00%May 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Jeffrey A. MecklerCo-Chief Executive Officer, Director229,9290.17%Feb 13, 2026
Michael James NewmanCSO and Director1,469,4301.10%Dec 29, 2025
Junyi DaiChief Executive Officer11,250,0008.44%Apr 2, 2026
Walt Addison LinscottChief Operating Officer54,4260.04%Dec 29, 2025
Nir SassiChief Financial Officer26,7580.02%Dec 29, 2025
Qinglai LuDirector––Apr 20, 2026
David E. LazarDirector0–Mar 24, 2026
Jerome D. JabbourDirector––Feb 27, 2026
Matthew Charles McMurdoDirector25,0000.02%Feb 26, 2026
Avraham Ben-TzviDirector25,1000.02%Jan 22, 2026
David NatanDirector0–Jan 22, 2026
Hila KarahDirector––Jun 11, 2025
Mark John GilbertDirector––Jun 11, 2025
Anthony J. MaddalunaDirector6700.00%Jun 11, 2025
Roger PomerantzDirector––Jun 11, 2025
Robert MartellDirector––Jun 11, 2025
William B. HayesDirector––Jun 11, 2025
LION VENTURES Ltd SINO10% owner38,895,00029.19%Apr 2, 2026
Yun Yao10% owner41,991,00031.51%Apr 2, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Avraham Ben-Tzvi
Director
Jan 20, 2026Award+25,000––25,100
Michael James Newman
CSO and Director
Dec 22, 2025Award+52,204$2.03$105.97K101,074
Walt Addison Linscott
Chief Operating Officer
Dec 22, 2025Award+54,421$2.03$110.47K54,426
Jeffrey A. Meckler
Co-Chief Executive Officer, Director, 10% owner
Dec 22, 2025Award+216,617$2.03$439.73K229,929
Nir Sassi
Chief Financial Officer
Dec 22, 2025Award+26,758$2.03$54.32K26,758
Jeffrey A. Meckler
Chief Executive Officer, Director
Jul 27, 2025Award+6,068$8.30$50.36K13,312
Jeffrey A. Meckler
CEO and Director
Nov 25, 2024Award+42,553$1.18$50.21K202,859
Jeffrey A. Meckler
CEO and Director
Aug 8, 2024Award+84,932$1.83$155.43K160,306
Glen R. Anderson
10% owner
Aug 14, 2023Buy+23,934$2.34$56.01K1,190,400
Glen R. Anderson
10% owner
Aug 11, 2023Buy+35,064$2.12$74.34K1,166,466
Glen R. Anderson
10% owner
Aug 10, 2023Buy+44,354$1.94$86.05K1,131,402
Boyan Vesselinov Litchev
Chief Medical Officer
Dec 1, 2022Buy+500$1.87$9351,150
Boyan Vesselinov Litchev
Chief Medical Officer
Nov 22, 2022Buy+500$1.83$915650
Jeffrey A. Meckler
CEO and Director
Nov 21, 2022Buy+9,600$1.90$18.24K75,374
Jeffrey A. Meckler
CEO and Director
Nov 18, 2022Buy+400$1.76$70465,774
Jeffrey A. Meckler
CEO and Director
Sep 8, 2022Buy+10,308$2.80$28.86K65,374
Walt Addison Linscott
Chief Business Officer
Sep 7, 2022Buy+150$2.62$393150
Jeffrey A. Meckler
CEO and Director
Sep 7, 2022Buy+8,632$2.57$22.18K55,066
Jeffrey A. Meckler
CEO and Director
Sep 6, 2022Buy+1,060$2.44$2.59K46,434
Jeffrey A. Meckler
CEO and Director
Jun 6, 2022Buy+19,727$2.63$51.88K45,374
Boyan Vesselinov Litchev
Chief Medical Officer
Mar 2, 2022Buy+50$4.09$205150
Michael James Newman
CSO and Director, 10% owner
Feb 1, 2022Sale(10b5-1 plan)−14,130$5.00$70.65K1,368,356
Boyan Vesselinov Litchev
Chief Medical Officer
Jan 31, 2022Buy+100$4.65$465100
Michael James Newman
CSO and Director, 10% owner
Jan 31, 2022Sale(10b5-1 plan)−5,870$5.00$29.35K1,382,486
Jeffrey A. Meckler
CEO and Director
Nov 18, 2021Buy+11,187$5.82$65.11K25,647
Jeffrey A. Meckler
CEO and Director
Sep 14, 2021Buy+12,000$7.00$84.00K14,460

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
0.86%
1M shares short
Days to cover
4.0
At 0M shares a day
Change since last report
+33.0%
From 1M shares
Short volume, 20 days
66.3%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Indaptus Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 120,693 shares on Sep 10, 2026 over the last 90 days.

See a number that looks wrong?